Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Author:
- The NAVIGATOR Study GroupTGThe NAVIGATOR Study Group
Top Cited Papers
- 22 April 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (16) , 1477-1490
Abstract
It is not known whether drugs that block the renin–angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)Keywords
This publication has 36 references indexed in Scilit:
- Role of Lifestyle and Oral Anti-Diabetic Agents to Prevent Type 2 Diabetes Mellitus and Cardiovascular DiseaseThe American Journal of Cardiology, 2007
- Impaired Fasting Glucose and Impaired Glucose ToleranceDiabetes Care, 2007
- Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysisBMJ, 2007
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialThe Lancet, 2002
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose ToleranceNew England Journal of Medicine, 2001
- Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteriaThe Lancet, 1999
- Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes StudyDiabetes Care, 1997
- Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studiesDiabetes, 1997